ESR1 and breast cancer: However, Ahern et al. (2011) and Lash et al. (2011) in homologous models found that the genetic variants CYP2D6∗4, UGT1A8∗3, UGT2B7∗2, and UGT2B15∗2 did not modify the relapse rate of the disease in patients with ER+/TAM + BC.